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Background: Insulin resistance and hyperinsulinemia play a key role in the pathogenesis of polycystic ovary
syndrome (PCOS), which is characterized by hyperandrogenism, ovulatory dysfunction, and presence of polycystic
ovaries on pelvic scanning. Insulin resistance is significantly associated with the long-term risks of metabolic
syndrome and cardiovascular disease. Berberine has effects on insulin resistance but its use in women with PCOS
has not been fully investigated. In this paper, we present a research design evaluating the effects of berberine on
insulin resistance in women with PCOS.
Methods/design: This is a multicenter, randomized, placebo-controlled and double-blind trial. A total of 120 patients
will be enrolled in this study and will be randomized into two groups. Berberine or placebo will be taken orally for 12
weeks. The primary outcome is the whole body insulin action assessed with the hyperinsulinemic-euglycemic clamp.
Discussion: We postulate that women with PCOS will have improved insulin resistance following berberine
administration.
Trial registration: This study is registered at ClinicalTrials.gov, NCT01138930.
Keywords: Berberine, Hyperinsulinemic-euglycemic clamp, Insulin resistance, Polycystic ovary syndromeBackground
Polycystic ovary syndrome (PCOS) is one of most com-
mon conditions affecting women of reproductive age and
characterized by menstrual irregularities, signs of andro-
gen excess, and, in many cases, obesity. Increased insulin
resistance and compensatory hyperinsulinemia play a key
role in the pathogenesis of PCOS [1,2]. Therefore, insulin-
sensitizing agents have been studied in the management
of PCOS.
Insulin-sensitizing agents include metformin and
thiazolidinediones such as troglitazone, rosiglitazone,
and pioglitazone. Metformin has been widely evaluated
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reproduction in any medium, provided the orshowed that it is of no benefit in improving weight loss,
insulin sensitivity, or lipid profiles in women with PCOS
[3]. Moreover, it was also associated with a significantly
higher incidence of gastrointestinal disturbance, leading
to a higher dropout rate in clinical trials. Troglitazone,
which underwent some trials for PCOS, was withdrawn
from the market because of liver damage after both
short- and long-term troglitazone treatment [4]. Al-
though rosiglitazone and pioglitazone do not carry the
same degree of risk of hepatotoxicity, these two drugs
are classified as pregnancy category C drugs according
to the Food and Drug Administration due to the po-
tential risk of causing fetal growth restriction in animal
experiments [5]. A high incidence of weight gain
among the users further hampers their use in obese
women with PCOS [6,7]. A Cochrane review indicated
that insulin resistance in women with PCOS could behis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ceutical interventions [8].
Berberine, the major active component of rhizomacoptidis,
exists in a number of medicinal plants and displays a
broad array of pharmacological effects [9]. In Chinese
medicine, berberine has long been used for its anti-
diabetic effects. Recently, berberine has been shown to
have positive effects on type 2 diabetes mellitus, insulin
resistance, lipid metabolism, nitric oxide production, and
metabolic syndrome [10-13].
The mechanisms of berberine in treating PCOS are still
unclear. The beneficial metabolic effects of berberine in
diabetic animals and type 2 diabetes mellitus patients are
through the activation of AMP-activated protein kinase
(AMPK) [11,14], which is similar to metformin. Metfor-
min was reported to have a direct effect on steroidogenesis
by ovarian cells in culture [15] and its ability to attenuate
androgen production by ovarian theca cells is mediated
through activation of AMPK [16]. In dexamethasone-
induced insulin resistant theca cells and granulosa cells, this
metabolic phenotype exaggerates androgenic potentials
within these cells [17,18]. Berberine was found to improve
insulin resistance in theca cells and granulosa cells in a way
similar to metformin [19]. Therefore, we hypothesize that
berberine could also have the same androgen production
regulation effects as metformin within PCOS.
There is only one published study of berberine used in
women with PCOS [20]. Eighty-nine Chinese PCOS
women with insulin resistance were randomized into
one of three treatment groups: berberine + cyproterone
acetate (CPA) (n = 31), metformin + CPA (n = 30), and
placebo + CPA (n = 28), for three months. Treatment
with berberine + CPA in comparison to metformin +
CPA showed a decreased waist circumference and waist-
to-hip ratio (P <0.01), decreased total cholesterol (TG)
and LDL-C (P<0.05), and increased HDL-C and sex hor-
mone binding globuline (SHBG) (P <0.05). Similarly, treat-
ment with berberine + CPA in comparison to placebo +
CPA showed a decrease in wrist-to-hip ratio (WHR),
fasting plasma glucose, fasting insulin, homeostasis model
assessment for insulin resistance (HOMA-IR), triglyceride
(TC), LDL-C, and TG (P<0.05) as well as an increase in
HDL-C and SHBG (P<0.01). The author concluded that
berberine, in comparison to metformin, showed similar
metabolic effects presumably on amelioration of insulin
sensitivity and reduction of hyperandrogenemia. Berberine
also appeared to have a greater effect on the changes in
body composition and dyslipidemia.
Berberine was used in combination with cyproterone
acetate in the abovementioned study and its effect on in-
sulin resistance in women with PCOS is still unclear.
Therefore, the aim of this study is to compare the insulin
resistance in PCOS patients with and without the use of
berberine.Methods/design
Study design
This is a multi-centered, randomized, double-blind,
placebo-controlled clinical trial. Reporting of the study re-
sults will follow the CONSORT statement [21]. Subjects
will be enrolled at four hospitals in mainland China: First
Affiliated Hospital of Heilongjiang University of Chinese
Medicine, First Affiliated Hospital of Harbin Medical
University, Fourth Affiliated Hospital of Harbin Medical
University, and First Affiliated Hospital of Guangzhou
Medical School.
This study has been approved by the ethics committee
of the First Affiliated Hospital of Heilongjiang University
of Chinese Medicine (2010HZYLL-012). Informed consent
will be obtained from each patient before any study pro-
cedure is performed according to good clinical practice.
This trial has already been registered at clinicaltrial.gov,
NCT01138930.
Participants
A total of 120 subjects will be recruited at the clinics of
the participating hospitals if they fulfill the inclusion
criteria and do not have any exclusion criteria.
Inclusion criteria
1) Women aged between 18 and 35 years.
2) Confirmed diagnosis of PCOS according to the
modified Rotterdam criteria and all subjects must
have anovulation plus either polycystic ovaries and/
or hyperandrogenism.
3) Body mass index equal to or greater than 23 kg/m2.
4) With no desire of children within 6 month.
PCOS is defined by the modified Rotterdam criteria:
oligomenorrhea or amenorrhea, together with presence
of ≥12 antral follicles (≤9 mm) and/or ovarian volume
>10 mL on transvaginal scanning, and/or clinical/bio-
chemical hyperandrogenism. Oligomenorrhea is defined
as an intermenstrual interval >35 days and <8 menstrual
bleedings in the past year. Amenorrhea is defined as an
intermenstrual interval >90 days. Clinical hyperandro-
genism in mainland China is defined with a Ferriman-
Gallwey (FG) score ≥5 [22].
Exclusion criteria
1) Administration of other medications known to
affect reproductive function or metabolism within
the past three months, including oral
contraceptives, GnRH agonists and antagonists,
antiandrogens, gonadotropins, anti-obesity drugs,
Chinese herbal medicines, anti-diabetic drugs such
as metformin and thiazolidinediones, somatostatin,
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blockers.
2) Patients with other endocrine disorders including
21-hydroxylase deficiency, hyperprolactinemia,
uncorrected thyroid disease, suspected Cushing’s
syndrome.
3) Patients with known severe organ dysfunction or
mental illness.Interventions
Eligible patients will be randomized into one of the
two arms: berberine (0.5 g, three times/day) or placebo.
Berberine or placebo will be administrated orally for 12
weeks. Berberine and placebo were produced by the same
pharmaceutical company (Renhetang Pharmaceutical Co.,
Ltd. China). They have the same appearance, size, odor and
taste.Study specific visits and procedures
The trial has two phases: 12 weeks treatment with either
berberine or placebo and three months follow-up
(Figure 1).
Patients will attend six visits in total: screening visit,
baseline visit, two monthly visits, end-of-treatment visit,
and follow-up visit. Adverse events and concomitant
medications will be recorded during visits. An overview
of study visit is found in Table 1.Figure 1 Study flowchart.Randomization and allocation concealment
Subjects (n = 120) will be allocated randomly into one of
the two groups in a ratio of 1:1. The identification code
and random number, which are unique for each partici-
pant, were generated by an independent data center using
SAS 9.2, seed = 20111024, block = 30, rand = 4. The
investigators will get the randomization number through a
web-based system operated by the independent data
center (http://210.76.97.192:8080/xbj/). Subjects, investi-
gators, and physicians treating the patients will be blind to
the assignment.
Outcome measurements
Primary outcome
Whole body insulin action: in vivo insulin action be-
fore and after treatment will be assessed with the
hyperinsulinemic-euglycemic clamp. The glucose dis-
posal rate (GDR; mg/(kg×min)), defined as the amount of
glucose required to maintain stable blood glucose concen-
trations during the last 30 min of the clamping, will be
used to define insulin action. The cut-off value of GDR in
normal controls is (13.34 ± 1.41) mg/(kg×min) [23].
Secondary outcomes
1) Oral glucose tolerance test (OGTT): serum for
glucose, insulin, and c-peptide levels will be
determined.
2) Ovarian androgen biosynthesis: as measured by
human chorionic gonadotropin (hCG), stimulated
production of 17-hydroxyprogesterone (17-OHP),
androstedione,and testosterone.
3) Hormonal profile including: testosterone, sex
hormone-binding globulin (SHBG), follicle
stimulating hormone (FSH), luteinizing hormone
(LH), and dehydroepiandrosterone sulfate (DHEAS).
4) Fasting lipid metabolic profile: cholesterol,
triglycerides (TG), high density lipoprotein
cholesterol (HDL-C), and low density lipoprotein
cholesterol (LDL-C).
5) Renal and liver function tests.
6) Weight, waist/hip circumference, blood pressure, FG
score and acne before and after treatment.
7) Adverse events.
Data entry and quality control of data
Case Report Forms (CRFs) will be developed for
data entry and the electronic version will be imple-
mented in a web-based data management system at
http://medresman.org.
Quality control of data will be handled at three different
levels. The first level is the real-time logical and range
checking built into the web-based data entry system. The
investigators at the participating sites are required to
Table 1 Overview of study visits
Screening
visit
Baseline
visit
Monthly
visit 1
Monthly
visit 2
Monthly visit 3 and end-of-
treatment visit
Follow-up
visit
Physical exam X X X
Safety labs X X
Transvaginal ultrasound X X X
Fasting phlebotomy for study parameters X X
Hyperinsulinemiceuglycemic clamp X X
Query for adverse event and concomitant
medications
X X X X X
Query for menstrual period X X X X X X
Medication dispensing and accounting X X X
Physical examination: Height, weight, hip and waist circumference, blood pressure, FG score, acne.
Fasting phlebotomy: Serum for the Central Core Laboratory.
Transvaginal ultrasound: endometrial thickness, ovarian volume, antral follicle count, and size of ovarian cysts or developing follicles.
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is the remote data monitoring and validation that is the
primary responsibility of the data manager and program-
mer at the Data coordination center (DCC). The data
manager will conduct monthly comprehensive data
checks, as well as regular manual checks (within the data-
base system). Manual checks will identify more compli-
cated and less common errors. The data manager will
query sites until each irregularity is resolved. The third
level of quality control will be the site visits, where data in
our database will be compared against source documents.
Identified errors will be resolved between the DCC and
clinical sites. The visits will ensure data quality and patient
protection.
Sample size calculation and statistical analysis
We hypothesize that women with PCOS have an insulin
resistance comparable to that of type 2 diabetes pa-
tients. According to previous results of berberine on
type 2 diabetes [9], the GDR (the primary outcome) is
7.42 ± 2.37 mg/(kg×min) in the berberine group and
6.06 ± 2.21 mg/(kg×min) in the control group. The
sample size was estimated according to the parameters:
α = 0.05, β = 0.1, which results in 52/group. Considering
a 15% drop-out rate over the course of the study, 120
total patients will be enrolled; 60 patients in each group.
Statistical analysis of all data will be performed by a
dedicated statistician in a blind manner. One sample of
the Kolmogorov-Smirnov test will be used to test the
normal distribution of continuous variables. Continuous
variables will be given as mean ± standard deviation if
normally distributed, and as median (interquartile range)
if not normally distributed. Statistical comparison will be
carried out according to the intention to treat by
student’s t-test, Mann–Whitney U-test, Wilcoxon signed
ranks test for continuous variables, and χ2 test for
categorical variables, where appropriate. All statistical
analyses of the data will be performed using the SPSSprogram, version 16.0 (SPSS Inc., Chicago, IL, USA) and
a P value <0.05 will be considered statistically significant.
Subgroup analysis will be performed with respect to
hyperandrogenism, which will be determined by evidence
of hirsutism on physical examination or by hyperandro-
genemia (biochemical elevations in total testosterone or
free androgen index). Hirsutism in mainland China is
taken as a FG score ≥5 [22]. Since cut-off value for testos-
terone varies between laboratories, hyperandrogenemia
will be determined from local laboratories. Local cut-offs
will be determined by each site prior to study initiation.
The free androgen index (FAI) is calculated from measur-
able values for total testosterone and SHBG using the
following equation: (FAI = Total testosterone in nmol/L/
SHBG in nmol/L) × 100.
Trial status
The study was conceived and designed in 2008. The first
participant was randomized on December 25th 2011. At
the time of manuscript submission, we have recruited
114 patients and the recruitment is ongoing.
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